The global biopharmaceutical packaging market size was valued at USD 23.2 billion in 2025 and is projected to grow from USD 25.24 billion in 2026 to USD 49.56 billion by 2034, registering a CAGR of 8.80% during the forecast period (2026-2034). North America dominated the biopharmaceutical packaging market with a share of 39.8% in 2025.
Biopharmaceutical packaging includes specialized pharma packaging materials and systems designed to protect biologic medicines, vaccines, and other biotechnology-derived therapies during storage, transportation, and administration. These products are commonly classified under HSN Code 7010 (glass containers used for packing or conveying goods) and SIC Code 3086 (Plastics Foam Products).
The biopharmaceutical packaging market demand is driven by the production of biologic medicines, the need to maintain drug stability, and the use of injectable therapies. Pharmaceutical manufacturers are adopting prefilled syringes and specialized glass vials, contributing to biopharmaceutical packaging market growth.
Download a Free Sample To learn more about this report,
Shift toward Cold Chain Compatible Packaging Solutions
The biopharmaceutical packaging market analysis shows shift towards cold chain compatible packaging solutions to maintain the stability and quality of temperature sensitive biologics, vaccines, and cell and gene therapies. These solutions include insulated containers, temperature controlled shipping systems, and specialized packaging materials that help protect products during storage and transportation.
Integration of Advanced Barrier Materials in Biopharmaceutical Packaging
Advances in biopharma packaging material technology are shaping the biopharmaceutical packaging market through the integration of advanced barrier materials that protect sensitive drug formulations from moisture, oxygen, light, and external contaminants. High performance polymers, coated glass containers, and specialized closure systems help preserve product stability and maintain container integrity.
Supply chain disruptions are expected to have a high impact on the biopharmaceutical packaging market share due to dependence on pharmaceutical-grade glass, specialized polymers, and elastomers. The market is expected to follow a U-shaped recovery, as shortages of packaging materials, manufacturing delays, and transportation constraints can disrupt the market. The market is expected to grow at a CAGR of 8.80%, but supply chain constraints could lower this by 1.0 percentage point, resulting in a growth of around 7.80%. As supply conditions normalize, the biopharmaceutical packaging market growth is expected to gradually return to 8.80%.
The biopharmaceutical packaging market forecasts strategic investment activity driven by expansion of sterile packaging capacity, increased production of prefillable syringes and pharmaceutical vials, and development of advanced drug-delivery packaging systems.
Key Investment and Funding Activities in Biopharmaceutical Packaging Market, 2026
PCI Pharma Services
More than USD 1 billion
In April 2026, PCI Pharma Services announced investments exceeding USD 1 billion across its U.S. and European operations to expand sterile fill-finish capacity, prefilled syringe and cartridge lines, vial packaging, and drug-device combination assembly.
BD (Becton, Dickinson and Company)
USD 110 million
In January 2026, BD announced an investment to expand prefillable glass syringe production in Columbus, Nebraska. The project supports packaging and delivery requirements for biologics and GLP-1 medicines while strengthening U.S. manufacturing capacity.
Demand for Temperature-Controlled Packaging and Prefilled Syringes Packaging Drives Market
Demand for temperature-controlled biopharmaceutical packaging is supporting the market as biologics, vaccines, and other sensitive medicines often require specific temperature conditions to maintain their stability and effectiveness. Insulated containers, specialized shipping systems, and temperature-monitoring solutions help protect these products during storage and transportation.
Adoption of prefilled syringes and ready-to-use packaging is contributing to market growth as healthcare providers seek convenient and reliable ways to prepare and administer injectable medicines. These packaging formats can reduce manual handling, simplify dose preparation, and help lower the risk of contamination during administration.
Stringent Regulatory Compliance Requirements and Compatibility Issues Between Packaging Materials and Biologic Drugs Restrain Market Expansion
Biopharmaceutical packaging must meet strict regulatory requirements to ensure product safety, sterility, stability, and quality throughout storage and transportation. Manufacturers must conduct extensive testing, validation, and documentation to demonstrate that packaging materials protect sensitive biologic products.Biologic drugs are sensitive to interactions with packaging materials, which may cause protein aggregation, product degradation, or the release of unwanted substances into the formulation. Selecting suitable containers, closures, and protective materials requires extensive compatibility and stability testing.
Expansion of Biologics and Biosimilars and High-Performance Packaging Materials Offers Growth Opportunities
Packaging manufacturers can target biopharmaceutical companies seeking containers and closures compatible with sensitive drug formulations. Materials such as pharmaceutical-grade glass, specialized polymers, and coated elastomers can help reduce the risk of contamination, chemical interactions, and product degradation. Revenue opportunities arise through advanced material sales, customized container development, compatibility testing services.
Biopharmaceutical packaging manufacturers can target pharmaceutical companies and biotechnology firms developing biologics, biosimilars, and injectable therapies. These products require biopharmaceutical packaging solutions that maintain product stability, protect against contamination, and support safe storage and transportation.
Primary packaging dominated the packaging type segment with a 54% share, reflecting its direct contact with biopharmaceutical products and its role in maintaining drug quality, sterility, and stability. Vials, syringes, and other primary packaging formats help protect sensitive biologic medicines throughout storage and distribution.
Primary closure components are projected to grow at a CAGR of 9.5% during the forecast period, driven by the need for reliable sealing systems that prevent contamination, leakage, and product degradation.
Request Customizationto receive a tailored report.
Vials held the leading position in the container format segment with a share of 32% in 2025, supported by their widespread use for storing injectable biologics, vaccines, and other temperature-sensitive medicines.
Pre-filled syringes will expand to 10.8% CAGR during the forecast period, fueled by demand for convenient, ready-to-administer injectable medicines. These formats can reduce preparation steps, support accurate dosing, and improve administration efficiency in clinical and homecare settings.
Biologics accounted for the largest share at 65%, owing to the extensive use of therapeutic proteins, monoclonal antibodies, and other biological medicines. These products often require specialized packaging to maintain stability, sterility, and protection against environmental exposure.
Advanced biotherapeutics segment will achieve a growth rate of 12.5% during the forecast period, supported by increasing development of cell therapies, gene therapies, and other advanced treatment modalities.
Commercial packaging represented the largest share at 33% in 2025, supported by the packaging requirements of approved biopharmaceutical products supplied to healthcare providers and patients.
The clinical trial packaging segment is projected to grow at a CAGR of 10.5% during the forecast period, fueled by the need for specialized packaging in clinical research. Clinical trial supplies require accurate labeling, traceability, controlled storage, and packaging configurations suited to trial protocols and investigational medicines.
Speak to an Analystto discuss market opportunities.
North America's biopharmaceutical packaging market accounted for a dominant share of 39.8% in 2025.
The U.S. Food and Drug Administration (FDA) provides specific guidance on container-closure systems for biologics, covering packaging materials, container integrity, and protection against contamination or product deterioration. These requirements support the use of specialized vials, prefilled syringes, and sterile pharmaceutical packaging designed to maintain the quality and stability of biologic medicines.
Health Canada’s biologic drug regulatory framework requires manufacturers to demonstrate that packaging components are suitable for their intended use and protect product quality throughout storage and distribution. These requirements support the use of validated container-closure systems and temperature-compatible packaging for vaccines, injectable biologics, and other sensitive pharmaceutical products.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific biopharmaceutical packaging market is expected to experience a growth rate of 10.2% during the forecast periodm making it the fastest growing region.
India’s vaccine manufacturing sector requires specialized packaging for vaccine vials, secondary cartons, and temperature-controlled distribution. The World Health Organization has prequalified vaccine carriers manufactured in India that maintain specified temperature conditions during transport, highlighting domestic capabilities in cold chain packaging for temperature-sensitive biological products.
In China, the pharmaceutical packaging industry is showcasing specialised solutions for biologics packaging and injectable medicines, including sterile vials, ampoules, prefilled syringes, and high-barrier packaging materials. Dedicated pharmaceutical packaging exhibitions in Shanghai feature these technologies, reflecting the role of primary packaging in protecting sensitive biological formulations and maintaining product integrity.
Japan introduced larger temperature-controlled rail containers for pharmaceutical transportation through collaboration among pharmaceutical and logistics organisations. The 31-foot containers provide increased capacity for temperature-sensitive medicines while maintaining controlled transport conditions, demonstrating the development of cold chain logistics and packaging systems for pharmaceutical distribution.
Europe's biopharmaceutical packaging market is expected to achieve a growth rate of 7.8% during the forecast period.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) implemented updated medicine packaging arrangements under the Windsor Framework, requiring new medicine packs supplied to the UK market to carry a clearly visible “UK Only” label. This change requires pharmaceutical manufacturers to adapt packaging artwork, carton layouts, and labelling workflows for biologic drugs and vaccine products.
SCHOTT Pharma, Takeda, and Corplex completed their first full delivery of pharmaceutical vials packed in trays containing recycled polypropylene. The initiative advances secondary pharmaceutical packaging by introducing recycled materials into vial transport trays while maintaining pharmaceutical quality requirements.
The Latin America biopharmaceutical packaging market is projected to grow at a CAGR of 8.9% during the forecast period. Brazil’s Butantan Institute operates vaccine manufacturing facilities that require pharmaceutical-grade glass vials, rubber stoppers, and sealed containers to maintain vaccine sterility and product integrity.
Mexico’s pharmaceutical glass packaging sector supplies containers such as Type I borosilicate glass vials and ampoules for injectable medicines and biologics. These containers offer chemical resistance and help protect sensitive formulations from contamination, making them important components of aseptic packaging and biologic drug packaging operations.
The Middle East & Africa biopharmaceutical packaging market is estimated to register a growth rate of 8.5% during the forecast period. Abu Dhabi’s Emirates Drug Establishment supports the UAE’s pharmaceutical manufacturing ecosystem, including local production of medicines and biologics. This creates opportunities for specialty primary pharmaceutical packaging, such as sterile vials and prefilled syringes.
South Africa’s public immunization programs require specialized packaging for vaccines distributed through healthcare facilities, including sterile glass vials, tamper-evident closures, and protective secondary cartons. These packaging components help maintain product integrity and sterility during storage and distribution.
The biopharmaceutical packaging market competitive landscape is highly fragmented, with established pharmaceutical packaging manufacturers and medical packaging solution companies. Key players such as West Pharmaceutical Services, SCHOTT Pharma, Gerresheimer, Stevanato Group, and Nipro are estimated to account for 30–35% of the global biopharmaceutical packaging market share.
Established players compete mainly through packaging material quality, container integrity contamination prevention, and specialized packaging for biologic drugs. Emerging and regional players in the biopharmaceutical packaging market ecosystem focus on advanced barrier materials, ready-to-use packaging formats, and application-specific packaging.
October 2026: Billerud launched PharmaKraft, a fiber-based packaging material designed for non-sterile pharmaceutical applications, including sachets, stick packs, strip packs, and blister lidding.
April 2026: SCHOTT Pharma announced cartriQ BioPure, a sterile glass cartridge designed for sensitive biologics, including monoclonal antibodies and fusion proteins.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Priyanka Nichite is a market research professional with over three years of experience supporting strategic intelligence across the chemicals, energy, and power sectors. She specializes in market sizing, industry analysis, competitive assessment, demand analysis, trend evaluation, and strategic research.
Her work focuses on understanding market structures, growth drivers, technology developments, regulatory influences, investment patterns, and competitive dynamics. Priyanka has contributed to research covering chemical products, industrial applications, energy technologies, power generation, and electrical infrastructure.
Paper Packaging Market Size, Share, Growth, 2034
Food Packaging Market Size, Share, Growth, Analysis, 2034
Packaging Market Size, Share, Growth, Analysis, Report, 2034
Pallets Market Size, Share, Growth, Analysis, Report, 2034
Water-Based Coated Film Market Size, Forecast, Demand, Opportunities, 2034
Solvent-free Packaging Film Market Size, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com